Abstract
Perindopril, an ACE inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, are established antihypertensive agents with complementary mechanisms of action. Recently, a once-daily, orally-administered, fixed-dose combination (FDC) of perindopril arginine plus amlodipine besylate (Prestalia(®); hereafter referred to as perindopril/amlodipine FDC) was approved in the USA for the treatment of hypertension. This article reviews the efficacy and tolerability of perindopril/amlodipine FDC and briefly summarizes the agent's pharmacologic properties. As demonstrated in short-term randomized controlled trials, perindopril/amlodipine FDC was significantly more effective in reducing blood pressure (BP) than monotherapy with either of the component drugs, and it appeared to be more effective than an up-titration scheme using valsartan and valsartan/amlodipine. The FDC agent was generally well tolerated, with the most common adverse events (peripheral edema, cough, headache, and dizziness) being consistent with the well-defined tolerability profiles of the individual component drugs. Furthermore, perindopril/amlodipine FDC was associated with a numerically lower incidence of peripheral edema compared with amlodipine monotherap...Continue Reading
References
Jul 1, 1991·Drugs·P A Todd, A Fitton
Jan 1, 1990·Drugs·R J MacfadyenJ L Reid
Jan 1, 1988·Journal of Cardiovascular Pharmacology·D A StopherM J Humphrey
Jul 1, 1986·British Journal of Clinical Pharmacology·J K FaulknerI W Taylor
Feb 1, 1988·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·A P BeresfordD A Stopher
Sep 1, 1995·Drugs·M Haria, A J Wagstaff
Jun 12, 2001·Drugs·M Hurst, B Jarvis
Sep 19, 2003·Lancet·K M Fox, UNKNOWN EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators
Dec 6, 2003·Hypertension·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Nov 13, 2004·JAMA : the Journal of the American Medical Association·Steven E NissenUNKNOWN CAMELOT Investigators
Sep 13, 2005·Lancet·Björn DahlöfUNKNOWN ASCOT Investigators
May 24, 2007·Current Medical Research and Opinion·Elwira Telejko
Aug 7, 2007·The American Journal of Medicine·Sripal BangaloreFranz H Messerli
May 26, 2009·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Vinay K BahlHemant P Thacker
Dec 23, 2009·Hypertension·Ajay K GuptaNeil R Poulter
Aug 10, 2010·Current Medical Research and Opinion·Jean-Jacques MouradMarilucy Lopez-Sublet
Feb 8, 2011·The American Journal of Medicine·Harikrishna MakaniFranz H Messerli
Mar 4, 2011·The Journal of Clinical Hypertension·Alan H GradmanUNKNOWN American Society of Hypertension Writing Group
Nov 6, 2012·Cardiovascular Therapeutics·Joel M Neutel, David H G Smith
Feb 23, 2013·Journal of the American Society of Hypertension : JASH·Yi ZhangJacques Blacher
May 18, 2013·Clinical Drug Investigation·Viktor L Nagy
Dec 3, 2013·Advances in Therapy·Luis Ruilope, Angie Schaefer
Dec 20, 2013·JAMA : the Journal of the American Medical Association·Paul A JamesEduardo Ortiz
Nov 8, 2014·Journal of Hypertension·Giuseppe ManciaJuan G Puig
Dec 6, 2014·Journal of Hypertension·Stéphane LaurentCsaba Farsang
Mar 26, 2015·Journal of the American Society of Hypertension : JASH·William J ElliottGeorge L Bakris
Mar 31, 2015·Journal of the American Society of Hypertension : JASH·William J Elliott
Citations
Sep 13, 2017·Chemistry : a European Journal·Rajdip Roy, Parthasarathi Dastidar
Jan 16, 2019·Heart Failure Reviews·Rabia JohnsonFaghri February
Feb 9, 2020·Journal of Clinical Laboratory Analysis·Tongtong WangYing Wang
Nov 4, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Kristyna KrasulovaPavel Anzenbacher
May 4, 2017·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Charalampos I LiakosVasilios T Kotsis
Jul 24, 2021·Molecular Medicine Reports·Jianfen ShenGuoxian Qi